Compare AbbVie Inc (ABBV) vs Carlyle Group Inc (CG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Carlyle Group Inc — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while Carlyle Group Inc trades at $42.82 (market cap $15.84B). The key difference: AbbVie Inc is far larger — about 28.4× Carlyle Group Inc's market cap, and Carlyle Group Inc pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| ABBV | CG | |
|---|---|---|
Market Cap | $449.91B | $15.84B |
Sector | Health | Financials |
52-Week High | $261.07 | $69.35 |
52-Week Low | $184.85 | $40.52 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Carlyle Group (CG) trades at $44.01, up 2.76% with a P/E of 30.16 and P/S of 5.61. Recent earnings show mixed results with Q4 2025 beat but Q1 2026 miss. Technical indicators signal bearish momentum with RSI at 76.93 suggesting overbought conditions. The company maintains strong analyst support with 14 buy ratings and a $59.60 consensus price target, representing 35% upside potential from current levels.
Carlyle demonstrates solid profitability with 18.85% net margin and 9.95% ROE, though revenue declined to $3.21B in 2025. Key risks include volatile cash flow from operations and execution challenges in fundraising targets. The stock offers growth potential through strategic acquisitions like MAI Capital Management, but investors should monitor earnings consistency and private credit exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
